# Study of Gecacitinib-corticosteroid as First-line Therapy for Grade II-IV Acute Graft Versus Host Disease

> **NCT07185633** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Bin Gu** · enrollment: 25 (estimated)

## Conditions studied

- aGVHD

## Interventions

- **DRUG:** Gecacitinib-Corticosteroid
- **DRUG:** Methylprednisolone sodium succinate

## Key facts

- **NCT ID:** NCT07185633
- **Lead sponsor:** Bin Gu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2026-10-01
- **Final completion:** 2027-10-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07185633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07185633, "Study of Gecacitinib-corticosteroid as First-line Therapy for Grade II-IV Acute Graft Versus Host Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07185633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*